- Home
- DNTH vs PEB Comparison
DNTH vs PEB Comparison
Compare DNTH & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- PEB
- Stock Information
- Founded
- DNTH 2015
- PEB 2009
- Country
- DNTH United States
- PEB United States
- Employees
- DNTH N/A
- PEB N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- PEB Real Estate Investment Trusts
- Sector
- DNTH Health Care
- PEB Real Estate
- Exchange
- DNTH Nasdaq
- PEB Nasdaq
- Market Cap
- DNTH 1.4B
- PEB 1.2B
- IPO Year
- DNTH N/A
- PEB 2009
- Fundamental
- Price
- DNTH $33.67
- PEB $10.47
- Analyst Decision
- DNTH Strong Buy
- PEB Hold
- Analyst Count
- DNTH 11
- PEB 8
- Target Price
- DNTH $65.22
- PEB $12.29
- AVG Volume (30 Days)
- DNTH 516.1K
- PEB 1.7M
- Earning Date
- DNTH 11-07-2025
- PEB 11-05-2025
- Dividend Yield
- DNTH N/A
- PEB 0.38%
- EPS Growth
- DNTH N/A
- PEB N/A
- EPS
- DNTH N/A
- PEB N/A
- Revenue
- DNTH $4,854,000.00
- PEB $1,469,933,000.00
- Revenue This Year
- DNTH N/A
- PEB $2.25
- Revenue Next Year
- DNTH N/A
- PEB $2.96
- P/E Ratio
- DNTH N/A
- PEB N/A
- Revenue Growth
- DNTH 17.87
- PEB 2.00
- 52 Week Low
- DNTH $13.37
- PEB $7.42
- 52 Week High
- DNTH $40.16
- PEB $15.12
- Technical
- Relative Strength Index (RSI)
- DNTH 46.99
- PEB 42.54
- Support Level
- DNTH $32.28
- PEB $10.56
- Resistance Level
- DNTH $35.40
- PEB $11.26
- Average True Range (ATR)
- DNTH 1.59
- PEB 0.34
- MACD
- DNTH -0.20
- PEB -0.04
- Stochastic Oscillator
- DNTH 26.53
- PEB 28.63
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.